| Name | Title | Contact Details |
|---|---|---|
Sean Murphy |
Chief Financial Officer | Profile |
Anni Goldberg |
Chief Human Resources Officer | Profile |
DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.
Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new
Metabolix, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases.